Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 4/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.51 |
| ▸ | PRCP | P42785 | 3/20 | 0.51 |
| ▸ | GBA1 | P04062 | 7/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10945126 | 1.00 | GNAI3 (0.51) | GNAI3GNAO1GNAI1PRCPGBA1 | |
| SCHEMBL10906234 | 0.98 | PRCP (0.49) | GNAI3GNAO1GNAI1PRCPGBA1 | |
| SCHEMBL2270943 | 0.92 | PRCP (0.42) | GNAI3GNAO1GNAI1PRCPGBA1 | |
| SCHEMBL7041937 | 0.86 | GNAI3 (0.56) | GNAI3GNAO1GNAI1PRCPGBA1 | |
| SCHEMBL7042804 | 0.86 | GNAI3 (0.56) | GNAI3GNAO1GNAI1PRCPGBA1 | |
| SCHEMBL3644949 | 0.84 | — | — | |
| SCHEMBL11302086 | 0.84 | GNAI3 (0.53) | GNAI3GNAO1GNAI1PRCPGBA1 | |
| SCHEMBL20192539 | 0.80 | RAD52 (0.31) | PRCP | |
| SCHEMBL7043466 | 0.78 | GNAI3 (0.50) | GNAI3GNAO1GNAI1PRCPGBA1 | |
| SCHEMBL1952601 | 0.78 | CXCR4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050101567-A1 | Substituted cyclic amine metalloprotease inhibitors | NATCHUS MICHAEL G (US) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101567-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | GNAI3 3551/4885GNAO1 3252/4885GNAI1 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.